Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 13Lung Neoplasms 5Mesothelioma 4Neoplasms 2NSCLC 2Recurrence 1Nonsquamous Non-small Cell Lung Cancer 1Non-squamous Non-small Cell Lung Cancer 1Mesothelioma, Malignant 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 2Gefitinib 2spartalizumab 1aflutinib 1Tyrosine Kinase Inhibitors 1Thalidomide 1Radiosurgery 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Axitinib 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × NSCLC × Pemetrexed × Clear all
NCT05209256 2022-01-26

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

The First Affiliated Hospital of Henan University of Science and Technology

Phase 2/3 Unknown
90 enrolled
Thoracic

NSCLC

NCT01769066 2016-02-23

Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC

Fudan University

Phase 2/3 Completed
117 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡